An immunohistochemical study of c‐erbb‐2 protein in gastric carcinomas and lymph‐node metastases: Is the c‐erbB‐2 protein really a prognostic indicator?

Ohguri, Takehiko; Sato, Yuichi; Koizumi, Wasaburo; Saigenji, Katsunori; Kameya, Toru

doi:10.1002/ijc.2910530115

Cited by 39 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various studies have not revealed an association of the c-ErbB-2 expression and prognosis in gastric cancer [25,26]. In our immunohistochemical study, c-ErbB-2 protein overexpression in patients with gastric carcinomas who received curative surgery had a tendency to a poor prog nosis.…”

Section: Discussionmentioning

confidence: 68%

Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain

et al. 1996

View full text Add to dashboard Cite

An immunohistochemical stain to the c-ErbB-2 protein was performed in 225 paraffin-embedded tissue blocks from patients with locally advanced gastric cancer who underwent curative resection. The overexpression of the c-ErbB-2 protein was observed in 27.4% of the patients. The c-ErbB-2 positivity showed a statistically significant correlation with nodal status and stage. The patients with an overexpression of the c-ErbB-2 protein had a tendency to a shorter survival than those without, but it was not statistically significant (p = 0.08). The 5-year survival rate after surgery was 54% in the negative staining group to the c-ErbB-2 protein and 49% in the positive staining group. This suggests that the c-ErbB-2 protein has a possible role in lymph node metastasis. Therefore overexpression of the c-ErbB-2 protein is a useful indicator of disease progression in gastric carcinoma patients who received curative surgery.

show abstract

Section: Discussionmentioning

confidence: 68%

Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain

et al. 1996

View full text Add to dashboard Cite

show abstract

“…The type of cytoplasmic staining could be classified as diffuse and granular. Diffuse cytoplasmic staining without membranous staining was noted in cases of gastric carcinoma [25], adenocarcinoma of the uterine cervix [27] and adenocarcinoma of Barrett's esophagus [28]. Granular cytoplasmic staining was seen in cases of breast carcinoma [21] and gastric carcinoma [10].…”

Section: Discussionmentioning

confidence: 96%

Immunohistochemical Study of c-erbB-2 Protein in Colorectal Cancer and the Correlation with Patient Survival

Osako¹,

Miyahara²,

Uchino³

et al. 1998

Oncology

104

View full text Add to dashboard Cite

We related events in immunohistochemical studies on formalin-fixed, paraffin-embedded preparations of 146 colorectal cancer patients. One hundred (68.5%) revealed cytoplasmic staining and only 3 of the 100 showed membranous staining. Western blot analysis revealed proteins with molecular masses of 185 and 155 kD following immunohistochemical membranous and cytoplasmic staining, but only a 155-kD protein following cytoplasmic staining. Amplification of the c-erbB-2 gene was detected in 2 of 44 cases (4.5%). Cytoplasmic c-erbB-2 overexpression correlated with tumor size (p < 0.01), subserosal invasion (p < 0.05), liver metastasis (p < 0.01) and Dukes’ classification. Overall survival rates and survival rates for Dukes’B patients were significantly lower in the group with cytoplasmic c-erbB-2 overexpression than in the group without cytoplasmic c-erbB-2 overexpression. Multivariate regression analysis showed cytoplasmic c-erbB-2 overexpression to be an independent prognostic factor for colorectal cancer. These results suggest that overexpression of cytoplasmic c-erbB-2 protein plays an important role in the progression of colorectal cancer and is considered to be an independent prognostic indicator of this lesion.

show abstract

“…Eighteen of 93 patients with gastric cancer (19%) had HER-2/neu overexpression, which was in line with previous reports. 10,19,22,23 The frequency of HER-2/neu overexpression in the carcinoma tissue of HLA-A2-positive and negative patients was almost equal at 20% and 19%, respectively. Moreover, there were no significant differences in the frequency of HER-2/neu status related to HLA-A11, A24, A26, B51 or Cw3 loci.…”

Section: Frequency Of Hla Haplotype Related To Her-2/neu Overexpressionmentioning

confidence: 97%

Frequencies of HER‐2/neu overexpression relating to HLA haplotype in patients with gastric cancer

Kono

Takahashi

Amemiya

et al. 2001

Intl Journal of Cancer

View full text Add to dashboard Cite

We have identified that HER-2/neu-derived peptides are naturally processed as tumor rejection antigens recognized by tumor-specific, HLA-A2-restricted cytotoxic T lymphocytes in gastric cancer. To evaluate candidates for immunotherapy using HER-2/neu-derived, HLA-A2-restricted peptides, we examined the frequency of HLA-A2 relating to HER-2/neu overexpression or the infiltrating grade of tumorinfiltrating lymphocytes (TILs) in Japanese patients with gastric cancer. HER-2/neu-overexpressing tumors detected by immunohistochemistry amounted to 19% of primary gastric cancers and HLA-A2-positive patients with gastric cancer were 31% of primary gastric-cancer cases. Finally, gastriccancer patients with both HLA-A2-positive and HER-2/neuoverexpressing tumors amounted to 6.6% of these cases. There was no significant difference in the infiltrating grade of TILs between gastric cancers overexpressing HER-2/neu and those that did not. Gastric cancer is 1 of the most common cancers occurring in Japan today. The control of gastric cancer at advanced stages still remains difficult, despite various treatments such as gastrectomy with extensive lymphadenectomy 1 and surgery combined with chemotherapy. 2 We and others reported that MHC class I-restricted cytotoxic-T lymphocytes (CTLs) from gastric-cancer patients can react specifically against autologous tumor cells. [3][4][5][6] Adoptive immunotherapy based on gastric cancer-specific CTLs, or vaccinations based on the MHC class I-associated tumor antigens that they recognize, represent alternative therapeutic approaches. The presence of tumor-associated antigens recognized by gastric-cancer-specific CTLs restricted by HLA-A31 6 or HLA-A2.1 molecules 4 has been demonstrated, although the nature of these antigens has not been defined. Moreover, we have identified that HER-2/neu-derived peptides are naturally processed as tumorassociated antigens recognized by tumor-specific, HLA-A2-restricted CTLs in gastric cancer. 7 Thus, HER-2/neu-derived peptides may be considered as candidates for tumor-specific immunotherapy such as tumor vaccination in patients with gastric cancer.The HER-2/neu protooncogene encodes a 185-kDa transmembrane glycoprotein with tyrosine-specific kinase activity. 8 The HER-2/neu protooncogene is amplified and overexpressed in approximately 30% of human ovarian and breast tumors 9 and in 20% of gastric cancers. 10 HLA-A2-restricted CTL epitopes derived from HER2/neu recognized by ovarian-11,12 and breast-13 cancerspecific CTLs have previously been defined, in addition to those specific for gastric cancer. The identification of several new HLA-A2-restricted CTL epitopes from HER-2/neu that can activate CTLs from healthy donors and patients with advanced ovarian carcinoma has also been reported. 14,15 These results indicate that HER-2/neu-derived peptides could be broad targets for immunotherapy against these types of cancers. It is important to evaluate candidates for tumor vaccination with HER-2/neu-derived peptides in patients with gastric cancer. Because it has...

show abstract

An immunohistochemical study of c‐erbb‐2 protein in gastric carcinomas and lymph‐node metastases: Is the c‐erbB‐2 protein really a prognostic indicator?

Cited by 39 publications

References 26 publications

Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain

Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain

Immunohistochemical Study of c-erbB-2 Protein in Colorectal Cancer and the Correlation with Patient Survival

Frequencies of HER‐2/neu overexpression relating to HLA haplotype in patients with gastric cancer

Contact Info

Product

Resources

About